



MEDI LIFESTYLE LIMITED

(Company Registration Number 201117734D)
(Incorporated in the Republic of Singapore on 26 July 2011)

EXO+ SERUM REGISTERED WITH NATIONAL PHARMACEUTICAL REGULATORY AGENCY OF MALAYSIA

The Board of Directors (the "**Board**" or "**Directors**") of Medi Lifestyle Limited (the "**Company**", and together with its subsidiaries, the "**Group**") is pleased to announce that the Company's indirect wholly owned subsidiary, HealthPro Marketing Sdn Bhd ("**HPP**") received acknowledgement from Malaysia's National Pharmaceutical Regulatory Agency ("**NPRA**") to market the Group's in-house brand of high purity exosomes under the name, '**Exo+ Serum**'.

Brand Name: **Exo+ Serum**

Product Name: **Exo+ Serum**

Product Notification No: NOT230800471K (Valid until 02 August 2025)

Human MSC (Mesenchymal Stem Cell) derived Exosomes, a subset of extracellular vesicles, play a vital role in cell-to-cell communication, functioning as carriers of nucleic acids, functional proteins, and other metabolites. Their clinical applications as diagnostic biomarkers and therapeutic transporters have also garnered substantial interest and financial investment in recent years. With the ability to transfer genetic information and proteins to various cells, exosomes establish essential pathways for intercellular communication. These messenger cells can trigger growth factors and other beneficial processes, making them a promising and innovative treatment option in diverse medical fields, including cancer therapy, tissue regeneration, and immune modulation. The potential of exosomes has sparked significant excitement in healthcare circles and holds immense promise for advancing medical treatments. Human MSC derived Exosomes with high purity could increase regenerative activity.

Dato Ken Low, Executive Director & CEO of the Company, commented, "With the product notification acknowledgement in hand, we are now poised to embark on a momentous journey of commercialization. Our sales and marketing teams have already commenced their strategic plans to introduce our high purity exosomes to healthcare professionals and patients alike. We are confident that our exosome products will gain rapid acceptance in the market due to the growing demand for advanced regenerative therapies."

Shareholders and other investors are reminded to exercise caution while dealing in the shares of the Company. In the event that shareholders and other investors are in doubt when dealing in the shares of the Company, they should consult their bankers, stockbrokers, solicitors or other professional advisers.

The Company will make the appropriate announcements as and when there are material developments.

By Order of the Board

Dato' Low Koon Poh
Executive Chairman and Chief Executive Officer
7 August 2023

MEDIA CONTACT

For media queries, please contact;

MEDI LIFESTYLE Limited

Corporate Communications Department

Tel: +65 6299 9881

Jeysie Wong (Mobile +60 13 257 2787, Email: jeysie.wong@medi-lifestyle.com)

*This announcement has been reviewed by the Company's sponsor, SAC Capital Private Limited ("**Sponsor**"). This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited ("**SGX-ST**") and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made, or reports contained in this announcement.*

The contact person for the Sponsor is Ms Charmian Lim, at 1 Robinson Road, #21-00 AIA Tower, Singapore 048542, telephone: (65) 6232 3210.